FDA Grants Approval for Genetically Engineered Salmon

Share this content:
FDA Grants Approval for Genetically Engineered Salmon
FDA Grants Approval for Genetically Engineered Salmon

FRIDAY, Nov. 20, 2015 (HealthDay News) -- The U.S. Food and Drug Administration approved on Thursday a Massachusetts company's request to produce genetically modified salmon.

"The FDA has thoroughly analyzed and evaluated the data and information submitted by AquaBounty Technologies regarding AquAdvantage Salmon and determined that they have met the regulatory requirements for approval, including that food from the fish is safe to eat," Bernadette Dunham, D.V.M., Ph.D., director of the FDA's Center for Veterinary Medicine, said at a media briefing.

After five years of study, the FDA didn't find any nutritional difference between the genetically modified salmon and conventional salmon, Durham said. The FDA isn't aware of any information that foods from genetically engineered sources differ from their non-genetically engineered counterparts or are less safe, she added.

Under FDA approval, AquaBounty Technologies cannot raise the salmon in the United States; it can only be raised on fish farms in Canada and Panama. Also, no other company is authorized to raise this type of fish for sale in the United States, the agency said. The FDA said it's convinced that measures will be put in place to prevent the genetically altered salmon from escaping from the farms and into the wild, so they wouldn't affect the environment. The FDA and the governments of Canada and Panama will inspect the facilities.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

CDC Concerned About Falling Flu Vaccination Rates

CDC Concerned About Falling Flu Vaccination Rates

Decline among vulnerable older adults is of particular concern

One in Five With Non-Valvular A-Fib Receiving Digoxin

One in Five With Non-Valvular A-Fib Receiving Digoxin

Indication for digoxin use was considered inappropriate in 59.8 percent in Turkish cohort

Rapid, Successful Response to ART for Many Patients With HIV

Rapid, Successful Response to ART for Many Patients ...

Factors associated with virological success include having undetectable viral load, use of three drugs

is free, fast, and customized just for you!

Already a member?

Sign In Now »